Metabolic profiling distinguishes three subtypes of Alzheimer's disease.
Level 4 - case-series / case-control
Case reports and case series presenting a descriptive classification without a control group
PubMed 26343025 · doi:10.18632/aging.100801
What was done
The author evaluated metabolic profiling and expanded laboratory testing in patients with dementia to classify subtypes of Alzheimer's disease based on clinical and biochemical features.
What was found
The abstract reports no numerical values, patient counts, or statistical results. It defines three clinical subtypes: an inflammatory subtype with elevated hs-CRP and globulin:albumin ratio; a non-inflammatory subtype with other metabolic abnormalities; and a young-onset cortical subtype characterized by early non-amnestic symptoms such as dyscalculia and aphasia, ApoE4-negative status, and zinc deficiency.
Why it matters
This framework characterizes Alzheimer's disease as clinically and biochemically heterogeneous, suggesting that metabolic abnormalities and micronutrient deficiencies may define distinct pathological presentations.
Limits
The abstract contains no sample size, control group, quantitative biomarker thresholds, or prospective validation metrics, representing an unvalidated descriptive classification.
Cited by
- partial Patients categorized with type 3 (toxic or cortical) Alzheimer's disease characteristically present with low serum zinc, elevated copper-to-zinc ratios, and low serum triglycerides.